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Immunodeﬁcient mice are becoming invaluable tools in human stem cell and tumor research. In this study, we generated
Rag-2/Jak3 double-deﬁcient (Rag-2−/−Jak3−/−) mice with a C57/BL6 and Balb/c genetic background and compared the human
lymphohematopoietic cell engraftment rate. Human cord blood-derived CD34+ hematopoietic stem cells were successfully
engrafted into Balb/c Rag-2−/−Jak3−/− mice; however, the engraftment rate was far lower in C57/BL6 Rag-2−/−Jak3−/− mice.
Transplantation of human peripheral blood mononuclear cells resulted in the same tendency. Thus, a Balb/c background oﬀers
superior engraftment capacity than a C57/BL6 background and provides an attractive model for human hematopoietic cell
engraftment.
1.Introduction
Animal models with a human hematopoietic and immune
system are now important tools for studying the human
immune system as well as human-speciﬁc infections, such
as HIV-1 [1, 2]. Recent approaches have involved the use of
genetically immunodeﬁcient mice that have been reconsti-
tuted using human-derived hematopoietic stem cells (HSCs)
(known as humanized mice). Several immunodeﬁcient mice
have been developed and NOD/Scid mice with NK defective
genetically modiﬁed mice are mainly used for this approach
[3–5], because they exhibit deﬁciencies in macrophage and
dendritic cell function, and complement as well as T and
B lymphocyte deﬁciencies [6]. Rag-2−/−γc−/− mice are also
commonly used for establishing humanized mice [7, 8],
and it is known that the genetic background of Rag-
2−/−γc−/− mice is inﬂuenced by the eﬃciency of human cell
engraftment.
JAK3 is a non-receptor-type tyrosine kinase crucial for
mediating signaling from the common γ-chain of cytokine
receptors, and Jak3-deﬁcient mice and common γ-chain-
deﬁcient mice show the same phenotype [9]. Based on these
ﬁndings, we generated Rag-2−/−Jak3−/− mice with C57/BL6
and Balb/c genetic backgrounds. These mice showed a lack
of mature T and B lymphocytes and NK cells. Balb/c Rag-
2−/−Jak3−/− mice showed high eﬃciency of both human
CD34+ hematopoietic stem cell (HSC) and peripheral blood
mononuclear cell (PBMC) transplantation compared with
C57/BL6 Rag-2−/−Jak3−/− mice. Our data show that the
genetic background of the mice inﬂuences human cell
engraftment and Balb/c Rag-2−/−Jak3−/− mice are becoming
an alternative source of humanized mice.
2.MaterialsandMethods
2.1. Mice. C57/BL6 Rag-2/Jak3 double-deﬁcient mice were
established by crossing Rag-2-deﬁcient mice [10] (obtained
from the Center for Animal Resources and Develop-
ment, Kumamoto University, Japan) and Jak3-deﬁcient
mice [11] (kindly provided by Dr. Takashi Saito). Balb/c
Rag-2-deﬁcient (Rag-2−/−) mice and Balb/c Jak3-deﬁcient2 Journal of Biomedicine and Biotechnology
(Jak3−/−) mice were established by crossing Rag-2−/− mice
or Jak3−/− mice with the Balb/c strain for 10 genera-
tions, respectively. Balb/c Rag-2/Jak3 double-deﬁcient (Rag-
2−/−Jak3−/−) mice were established by crossing Balb/c Rag-
2−/− mice and Balb/c Jak3−/− mice, and were housed and
monitored in our animal research facility according to
institutional guidelines. All experimental procedures and
protocols were approved by the Institutional Animal Care
and Use Committee at Kumamoto University.
2.2. Cell Preparation and Transplantation. Peripheral blood
and umbilical cord blood samples were collected after
obtaining written informed consent and approval from
the Ethics Committee of Kumamoto University Faculty of
Medical and Pharmaceutical Sciences. CD34+ cells were
isolated using the CD34 Progenitor Cell Isolation Kit
(Miltenyi Biotec, Sunnyvale, CA) and transplanted into the
liver of irradiated (4.0Gy) newborn mice. At 12 weeks after
transplantation, peripheral blood was obtained and analyzed
by ﬂow cytometry.
Peripheral blood mononuclear cells (2 × 107 cells) were
transplanted into 5.0Gy irradiated adult mice (8–10 weeks
old) as described [5]. At 2 weeks after transplantation,
peripheral blood was harvested and analyzed by ﬂow cytom-
etry.
2.3. Flow Cytometry. Mouse spleen cells were stained
with DX5-FITC (pan NK marker), mCD122 (IL-2Rβ)-PE,
mCD19-APC, and mCD3-PE/Cy7 (eBiosciences, San Diego,
CA)todetectmurinelymphocytes.Peripheralbloodsamples
were obtained from the retro-orbital sinus of transplanted
mice, and red blood cells were lysed with an ammo-
nium chloride-potassium buﬀer and stained with antimouse
CD45-APC/Cy7 and antihuman CD45-PB (Biolegends, San
Diego, CA). Cells were washed and resuspended in PBS
supplemented with 3% FCS, 0.02% NaN3, and 1μg/mL
propidium iodide and were analyzed using LSR II (BD
Biosciences, San Jose, CA). Data were analyzed with FlowJo
(Tree Star, San Carlos, CA).
2.4. Engraftment of K562 Cells. K562 cells (obtained from
RIKEN cell bank, Tsukuba, Japan) were cultured in
RPMI1640 medium (Sigma) supplemented with 10% FBS,
and were transplanted subcutaneously into the right ﬂank of
C57/BL6 Rag-2−/−Jak3−/− mice and Balb/c Rag-2−/−Jak3−/−
mice. The tumors were removed and weighed 21 days after
transplantation.
2.5. Statistical Analysis. The statistical signiﬁcance of diﬀer-
ences was determined using Student’s t-test. P values less
than .05 were deﬁned as signiﬁcant.
3. Results
3.1. Characterization of Rag-2−/−Jak3−/− Mice. The gen-
erated C57/BL6 Rag-2−/−Jak3−/− mice and Balb/c Rag-
2−/−Jak3−/− mice survived and bred well under the spe-
ciﬁc pathogen-free conditions. To conﬁrm the predicted
immunophenotype of C57/BL6 Rag-2−/−Jak3−/− mice and
Balb/c Rag-2−/−Jak3−/− mice, single-cell suspensions from
spleen cells were labeled with ﬂuorescent antibodies against
mouse DX-5 (pan NK marker), CD122 (IL-2Rβ), CD3 (T-
cell marker), and CD19 (B-cell marker). In contrast to wild-
type mice, no B (CD20 positive) and T (CD3 positive)
lymphocytes or NK cells (DX-5 and CD122 double-positive
cells) were detected in either C57/BL6 or Balb/c Rag-
2−/−Jak3−/− mice (Figure 1).
3.2. Engraftment with Human Hematopoietic Stem Cells. To
determine the engraftment eﬃciency of human hematopoi-
etic stem cells, 2 × 105 cord blood-derived CD34+ cells
from normal volunteers were injected intrahepatically into
C57/BL6 Rag-2−/−Jak3−/− mice and Balb/c Rag-2−/−Jak3−/−
mice as described [5, 7]. Levels of human cell engraft-
ment were determined 12 weeks later (Figure 2(a)). Of the
engrafted C57/BL6 Rag-2−/−Jak3−/− m i c e ,1 8o f2 8m i c eh a d
less than 0.1% of human CD45+ cells, and only 2 had >10%
human CD45+ cells in the peripheral blood (1.7±4.5%, n =
28). In contrast, Balb/c Rag-2−/−Jak3−/− mice were highly
engrafted and reconstituted with human cells (37.8±21.5%,
n = 24) (Figure 2(b)).
3.3. Engraftment with Human PBMC. To determine the
engraftment eﬃciency of human primary lymphocyte pop-
ulations, 2 × 107 PBMCs from normal volunteers were
injected intraperitoneally into C57/BL6 Rag-2−/−Jak3−/−
mice and Balb/c Rag-2−/−Jak3−/− mice. Levels of human
cell engraftment were determined 2 weeks later. Although
human cells (human CD45+ cells) were detected in C57/BL6
Rag-2−/−Jak3−/− mice, the degree of engraftment was very
low(1.7±4.5%,n = 13).Incontrast,Balb/cRag-2−/−Jak3−/−
mice were highly engrafted with human cells (37.8 ± 21.5%,
n = 12) (Figure 3).
3.4. Tumor Cell Engraftment. The ability of Rag-2−/−Jak3−/−
mice to engraft human hematopoietic malignancies was
examined. Subcutaneous administration of K562 cells
resulted in solid tumor formation in both strains of Rag-
2−/−Jak3−/− mice. The mice were sacriﬁced and subcuta-
n e o u st u m o r sw e r er e m o v e da n dw e i g h e d .T h ew e i g h to f
tumors in both strains showed no signiﬁcant diﬀerence
(C57/BL6: 0.59 ± 0.26g, n = 7, Balb/c 0.63 ± 0.33g, n = 7,
P>. 05) (Figure 4).
4. Discussion
In this study, we established C57/BL6 and Balb/c strains
of Rag-2−/−Jak3−/− mice, and showed that Balb/c Rag-
2−/−Jak3−/− mice supported a high level of human lym-
phohematopoietic cell engraftment, whereas C57/BL6 Rag-
2−/−Jak3−/− mice achieved little engraftment. Interest-
ingly, both strains supported the engraftment of human
hematopoietic malignancy.
Humanized mice with reconstituted human hematopoi-
etic and immune cells are becoming a powerful tool for
the investigation of human biological systems and forJournal of Biomedicine and Biotechnology 3
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Figure 1: Lack of mature lymphocytes and NK cells in both Balb/c and C57/BL6 background Rag-2−/−Jak3−/− mice. Spleen cells from
C57/BL6 wild-type mice, Rag-2−/−Jak3−/− mice and Balb/c wild-type mice, and Rag-2−/−Jak3−/− mice, were stained with DX5-FITC (pan
NK marker), CD122 (IL-2Rβ), CD19-APC, and CD3-PE/Cy7. No T and B lymphocytes or NK cells were observed in the spleen of Rag-
2−/−Jak3−/− mice.
translational research [2]. NOD/Scid mice have been used
for these purposes; however, human hematopoietic stem
cell engraftment is not suﬃcient and functionally mature
lymphocytes are not developed in these mice, mostly due
to residual NK activity in this mouse. To overcome these
limitations, NOD/Scid mice were intercrossed with NK
defective genetically modiﬁed mice, and several strains of
mice suitable for humanized mice were established [3–
5]. Among them, NOD/Scid/γc−/− (NOG and NSG) mice
are becoming the gold standard for generating humanized
mice. Recently, Spira gene polymorphism has been iden-
tiﬁed as a determinant inﬂuencing the eﬃcacy of human
hematopoietic stem cell engraftment into the NOD/Scid
strain [12]. Meanwhile, Stroma cells of the Balb/c strain have
been shown to support human hematopoiesis to a lesser
extentbutnototherstrains(C57/BL6,C3H,ICR),indicating
that other mechanisms support human cell engraftment
in immunodeﬁcient mice than Spira gene polymorphism.
In fact, Manz and colleagues described the reconstitution
of human acquired and innate immunity in Balb/c Rag-
2−/−γc−/− mice [7]. Although no study has compared
reconstitution eﬃciency directly between NOD/Scid/γc−/−
mice and Balb/c Rag-2−/−γc−/− mice, the eﬃciency of
human hematopoietic stem cell engraftment seems to be
higher in NOD background from the previous studies
[1, 2]. However, the eﬃciency of reconstitution in Balb/c
Rag-2−/−γc−/− mice is high enough for human immune
and hematopoietic cell research (Figures 2 and 3)a n d
Balb/c background has several advantages compared with
NOD/Scid background.
The NOD/Scid strain has several disadvantages [1]. Mice
with the scid mutation lack functional T and B lymphocytes
resulting from the absence of gene recombination events
in T-cell receptors (TCRs) and immunoglobulins; however,
they are known to show a leaky phenomenon in which
functional T and B lymphocytes are produced with aging
or ionized irradiation [13, 14]. In addition, the Prkdc gene
disrupted by the scid mutation is expressed broadly and is
involved in DNA repair, while expressions of Rag-1 and Rag-
2 are limited to hematopoietic cells and are involved only in
DNA recombination of T- and B-cell receptor genes, indi-
cating that scid mice are more sensitive to radiation-induced
DNA damage than their Rag-1−/− or Rag-2−/− counterparts.
Recently, T. Pearson et al. established radioresistant NOD
Rag-1−/−γc−/− mice and showed that they support a similar
level of human lymphohematopoietic cell engraftment [15],
which could overcome the disadvantages of the scid muta-
tion. The NOD/Scid strain has a predisposition to thymic
lymphoma due to an endogenous ectopic provirus (Emv-30)
[16]. NOD/Scid and NOD/Scid/β2m−/− mice have a short
mean life span for this reason [6, 17], while NOD/Scid/γc−/−
(NOG and NSG) mice do not develop thymic lymphoma
for an unknown reason [4]. Balb/c strain could overcome
these disadvantages of NOD/Scid strain, although eﬃciency
of human hematopoietic stem cell engraftment is not better
than NOD/Scid strain[1].
As the strain background is known to aﬀect human-cell
engraftment and to function markedly in scid mice [1, 2, 18],
we established and directly compared C57/BL6 and Balb/c
strains of Rag-2−/−Jak3−/− mice. Rag-2−/−Jak3−/− mice4 Journal of Biomedicine and Biotechnology
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Figure 2: Balb/c Rag-2−/−Jak3−/− mice support human hematopoietic stem cell engraftment more eﬃciently than C57/BL6Rag-2−/−Jak3−/−
mice. Cord blood-derived CD34+ cells (2 × 105 cells/ mouse) were transplanted into irradiated newborn mice intrahepatically. Peripheral
blood of CD34-transplanted recipients was obtained 12 weeks after transplantation, and human and murine chimerism was assessed by ﬂow
cytometry.
showed the same phenotype as Rag-2−/−γc−/− mice lacking
T, B, and NK cells [7]( Figure 1). The eﬃciency of human
hematopoietic stem cell and PBMC engraftment in C57/BL6
Rag-2−/−Jak3−/− mice was extremely poor, although Balb/c
mice and Rag-2−/−Jak3−/− mice appeared to have similar
levels as Balb/c Rag-2−/−γc−/− mice (Figures 2 and 3)[ 8].
ThebreedingperformanceofBalb/cRag-2−/−γc−/− micewas
the same as Balb/c mice in our study. In addition, Balb/c
Rag-2−/−γc−/− mice were relatively radioresistant compared
with NOD/Scid strains. Thus, Balb/c Rag-2−/−Jak3−/− mice
are a very useful strain of immunodeﬁcient mice derived
from animals with deﬁned molecular lesions and have
distinct advantages over NOD/Scid-based immunodeﬁcient
mice.
5. Conclusion
In conclusion, we established C57/BL6 and Balb/c strains
of Rag-2−/−Jak3−/− mice and showed that Balb/c Rag-
2−/−Jak3−/− mice enabled high human hematopoietic cell
engraftment.Journal of Biomedicine and Biotechnology 5
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Figure 3: Balb/c Rag-2−/−Jak3−/− mice support human peripheral blood mononuclear cells (PBMC) engraftment more eﬃciently than
C57/BL6 Rag-2−/−Jak3−/− mice. PBMC (2 × 107 cells/mouse) were transplanted into irradiated adult mice intravenously. Peripheral blood
of PBMC transplanted recipients were obtained 12 weeks after transplantation, and human and murine chimerism was assessed by ﬂow
cytometry.
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Figure 4: Engraftment of K562 erythroleukemia cell line into
Rag-2−/−Jak3−/− mice. K562 cell line (5 × 106 cells/ mouse) was
subcutaneously transplanted into Rag-2−/−Jak3−/− mice. Three
weeks after transplantation, mice were sacriﬁced and the tumors
weighed.
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